Author: Leona Whitmore - Page 2

Feb, 4 2026
Leona Whitmore 10 Comments

Future of Global Generic Markets: Key Predictions and Trends for 2025-2030

Explore the future of global generic drug markets with key predictions for 2025-2030. Learn about growth drivers, challenges, regional trends, and how biosimilars are reshaping affordable healthcare.

View more
Feb, 3 2026
Leona Whitmore 10 Comments

Medications Safe During Pregnancy: A Complete Patient List

A clear, evidence-based list of medications safe during pregnancy, including dosages, alternatives, and what to avoid. Covers pain relief, allergies, nausea, heartburn, and prescription drugs with expert guidance and real-world tips.

View more
Feb, 2 2026
Leona Whitmore 10 Comments

Night vs Morning Statin Dosing: What Really Matters for Side Effects and Effectiveness

The best time to take statins isn't night or morning - it's whenever you'll remember. Newer statins work equally well anytime; adherence matters more than clock time.

View more
Feb, 1 2026
Leona Whitmore 12 Comments

How to Talk to Your Doctor About Staying on a Brand Medication

Learn how to talk to your doctor about staying on a brand medication when generics aren't working for you. Get practical tips on documenting side effects, using SBAR, and appealing insurance denials.

View more
Jan, 31 2026
Leona Whitmore 15 Comments

How to Build a Personal Medication Safety Plan with Your Care Team

Learn how to create a personalized medication safety plan with your care team to prevent dangerous drug interactions, reduce side effects, and avoid accidental overdoses. Simple steps can save your life.

View more
Jan, 30 2026
Leona Whitmore 9 Comments

AI and Pharmacogenomics: How Personalized Generic Medication Recommendations Are Changing Online Pharmacies

AI is transforming how online pharmacies recommend generic drugs by using your genes to predict what’s safe and effective. Learn how pharmacogenomics works, where to get started, and why this could prevent dangerous side effects.

View more
Jan, 29 2026
Leona Whitmore 12 Comments

Manufacturing Changes: Notification and Approval Requirements in Pharmaceutical Production

Understand the regulatory requirements for manufacturing changes in pharmaceutical production, including FDA, EMA, and Health Canada rules for notification, approval, and compliance. Learn how to classify changes correctly and avoid costly violations.

View more
Jan, 28 2026
Leona Whitmore 9 Comments

FDA Listing for Biosimilars: How They Are Evaluated and Approved

The FDA doesn't rate biosimilars like generics-they undergo a rigorous scientific review to prove they're highly similar to the original biologic. Learn how approval works, what 'interchangeable' means, and why biosimilars are changing access to expensive treatments.

View more
Jan, 26 2026
Leona Whitmore 10 Comments

How to Report Medication Side Effects to Your Healthcare Provider Effectively

Learn how to clearly report medication side effects to your healthcare provider so your concerns are taken seriously and contribute to safer drug use for everyone. Includes practical steps, tools, and what happens after you speak up.

View more
Jan, 26 2026
Leona Whitmore 15 Comments

Authorized Generics vs Brand Drugs: What You Need to Know About These Identical Medications

Authorized generics are identical to brand-name drugs in every way-same ingredients, same manufacturer, same effectiveness. Learn how they differ from regular generics and when to ask for them at the pharmacy.

View more
Jan, 24 2026
Leona Whitmore 12 Comments

Paragraph IV Certifications: How Generic Drug Makers Legally Challenge Patents

Paragraph IV certifications let generic drug makers legally challenge brand-name patents before launch. This Hatch-Waxman Act mechanism saves billions in healthcare costs and drives generic competition in the U.S.

View more
Jan, 24 2026
Leona Whitmore 15 Comments

Paragraph IV Certifications: How Generic Drug Makers Legally Challenge Brand Patents

Paragraph IV certifications let generic drug makers legally challenge brand-name patents before market entry. This Hatch-Waxman Act tool drives competition, saves billions, and offers 180-day exclusivity to winners - but only if they navigate complex legal risks.

View more